Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Azacitidine and Venetoclax Versus Allogeneic Stem Cell Transplant in Older Patients With AML
NCT06903702Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of azacitidine, venetoclax in acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Aug 2026; status: withdrawn.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06903702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903702.